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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To determine the most effective and best-tolerated approaches for the treatment of elderly people with newly diagnosed glioblastoma.
To summarise current evidence for the incremental resource use, utilities, costs and cost-effectiveness associated with the different man-
agement strategies for newly diagnosed glioblastoma among adults aged over 70 years.
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B A C K G R O U N D
Description of the condition
Glioblastoma multiforme is a high grade, aggressive primary tu-
mour of the central nervous system with a poor prognosis. The in-
cidence of glioblastoma is increasing and this rise is most rapid in
the elderly (Ferguson 2014). Use of the term the ‘elderly' in rela-
tion to glioblastoma commonly refers to people over 70 years of age
(NCCN 2018). Age is an important consideration in the treatment
of glioblastoma as it is a negative prognostic indicator (Lorimer
2017). Median survival drops from 12 to 18 months for younger
people with glioblastoma, to three to six months for older age
cohorts (Brodbelt 2015). The molecular status of glioblastoma is
also an important prognostic factor and several molecular sub-
types of glioblastoma have been recognised (Lara-Velazquez 2017).
One of the most important molecular signatures is O6-methylgua-
nine-DNA-methyltransferase (MGMT) promoter methylation, which
has been shown to confer predictive and prognostic benefit (Malm-
strom 2012; Yin 2014). Treatment for glioblastoma is not curative
and the natural history of the disease is that patients will relapse
after treatment and it will ultimately be a fatal condition (Louis
2016). Retrospective studies have shown that older people are less
likely to get aggressive, multi-modality treatment (Iwamoto 2008;
Lorimer 2017; Paszat 2001), but people with glioblastoma across all
age groups who do get active treatment live longer (Brodbelt 2015).
Direct healthcare costs for the management of malignant gliomas
have been estimated at USD 32,764 per patient (2011 data; Raizer
2015).
Description of the intervention
The ‘standard of care' of treatment for patients aged under 70 years
of age with glioblastoma consists of surgery, followed by radiother-
apy (60 Gy in 30 fractions) and concurrent and adjuvant temozolo-
mide (TMZ) chemotherapy (Stupp 2005; NCCN 2018). This manage-
ment plan is less often used in the elderly for the following reasons.
• People over 70 years old were not included in the landmark trial
(Stupp 2005), and a subsequent communication of the results
of an exploratory subgroup analysis revealed that the survival
benefit in this trial was not statistically significant for subgroup
of people aged 66 to 70 years (Laperriere 2013).• Shorter radiotherapy courses or chemotherapy alone can lead
to better outcomes for the elderly than the standard course of
radiotherapy (Malmstrom 2012).• Treatment toxicity is often greater in the elderly (Lawrence 2011;
Sijben 2008).• The shorter predicted survival time for older people with
glioblastoma means that they might spend much of this time re-
covering from the six-week course of radiotherapy.
Small prospective (Vuorinen 2003), and retrospective studies
(Chaichana 2011a; Chaichana 2011b), have shown that, for people
aged 65 and over with glioblastoma, maximal debulking (resection)
is associated with better survival and a trend to longer time remain-
ing independent versus biopsy alone. Therefore maximal resection,
if feasible, is the recommended primary approach to glioblastoma
in the elderly (NCCN 2018). Depending on performance status, ra-
diotherapy or chemotherapy, or both, can then be added. As it
remains unclear which treatment is best for glioblastoma in the
elderly, participation in clinical trials is strongly encouraged (NC-
CN 2018). There is little evidence to guide treatment of recurrent
glioblastoma in the elderly and approaches are based on retrospec-
tive studies (Socha 2016).
Treatment with either radiotherapy or chemotherapy
A randomised trial of radiotherapy (50 Gy delivered over a period
of 5 to 6 weeks) versus best supportive care showed that radiother-
apy conferred a 12-week survival benefit in older people with ma-
lignant glioma (malignant glioma encompasses anaplastic glioma,
i.e. World Health Organization (WHO) grade 3 and 4) (Keime-Guib-
ert 2007). Another randomised trial found that radiotherapy (60 Gy
over a period of 6 to 7 weeks) was as effective as intensive ("dose-
dense") adjuvant temozolomide chemotherapy alone (Wick 2012).
There is increasing interest in using hypofractionated radiothera-
py (radiotherapy delivered over shorter period of time, e.g. 34.0 Gy
in 10 fractions over a period of two weeks) for older people with
glioblastoma, as it has been found to have similar survival benefits
compared to the standard regimen of 60 Gy in 30 fractions over a
period of six weeks (Malmstrom 2012; Roa 2004).
Combination treatment
A randomised trial has shown that adding TMZ to hypofractionat-
ed radiotherapy for older people with glioblastoma confers a sur-
vival advantage compared to hypofractionated radiotherapy alone
(Minniti 2012; Perry 2017), but not necessarily for those people with
MGMT unmethylated tumours.
How the intervention might work
Surgery is an important step in the treatment of glioblastoma. Also,
there is evidence that surgery improves one- and two-year survival
rates compared to biopsy alone (Brown 2016). The extent of surgery
can be divided into three main categories which have different de-
finitions in the literature: ‘maximal' debulking or gross total resec-
tion (GTR), subtotal resection (STR), and biopsy. The role of max-
imal debulking surgery is to minimise the tumour volume that re-
mains to optimise the impact of subsequent treatment modalities,
which are likely to be more effective against small volume tumours
(Lara-Velazquez 2017).
Radiotherapy is delivered to the primary tumour or the surgical cav-
ity with a margin to account for microscopic spread, patient move-
ment, and set-up error (Niyazi 2016). One of the most important
mechanisms of action of radiation therapy is the promotion of dou-
ble strand breaks in DNA which, if leM unrepaired, will result in cell
death (Baskar 2014). DNA damage is more likely to occur in rapidly
dividing cells, such as glioblastoma tumour cells, rather than nor-
mal brain which has a slower rate of cellular turn over. This provides
the therapeutic index between the tumour and normal surround-
ing tissue.
Systemic chemotherapy can enhance the therapeutic effect of ra-
diotherapy but is also an effective treatment on its own. The most
widely used chemotherapy agent is TMZ, which acts as a DNA
alkylating agent (Zhang 2012). Those tumours with MGMT pro-
moter methylation lack the MGMT enzyme which repairs the cyto-
toxic damage caused by TMZ, thereby making tumour cells more
chemosensitive.
Why it is important to do this review
Is it recognised that treating older people with glioblastoma
presents unique challenges and that the standard approach is not
always appropriate. There have been several randomised trials in
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recent years that have tested therapeutic strategies specifically for
older people with glioblastoma (e.g. Malmstrom 2012; Perry 2017;
Roa 2004; Wick 2012). Other trials including younger people have
also performed subgroup analysis to test if therapeutic benefit is
maintained in older people. Due to the variation in age thresholds
to define the ‘elderly', performance status, treatment regimens,
and molecular subtypes, it has been difficult to translate these in-
dividual studies into clinical practice. This is also because the fo-
cus of many intervention trials is on survival, which might not be
the most important outcome to elderly people with glioblastoma;
rather, the quality of the remainder of their life might be their most
important consideration.
Selecting the appropriate management strategy for an elderly pa-
tient group is important from a quality of life perspective and also
has significant resource implications (Raizer 2015). It has been es-
timated the average cost for a regimen of temozolomide to treat a
person with newly diagnosed glioblastoma is USD 46,693 (USD in
2018 converted from NZD 2005) (Hamilton 2005). It is therefore im-
portant to understand the cost and benefits to avoid implementing
costly and potentially toxic treatment for little clinical benefit.
Currently there is no clear consensus on how to apply the available
evidence to guide treatment of the individual person seen in clin-
ic. A systematic review and network meta-analysis of randomised
trials would help to inform the best approach to the treatment of
older individuals with newly diagnosed glioblastoma and help to
identify research gaps.
O B J E C T I V E S
To determine the most effective and best-tolerated approaches
for the treatment of elderly people with newly diagnosed glioblas-
toma.
To summarise current evidence for the incremental resource use,
utilities, costs and cost-effectiveness associated with the different
management strategies for newly diagnosed glioblastoma among
adults aged over 70 years.
M E T H O D S
Criteria for considering studies for this review
Types of studies• Randomised controlled trials (RCTs) for evidence on effective-
ness and safety.• Full economic evaluations (cost-effectiveness analyses, cost-
utility analyses, and cost-benefit analyses) conducted alongside
any study design and any model-based economic evaluations
for economic evidence.
Types of participants
Elderly people undergoing treatment for histologically confirmed
newly diagnosed glioblastoma. For the purpose of this Cochrane
Review, we define ‘elderly' as over the age of 70 years; however,
where investigators have defined the ‘elderly' as over 65 years of
age, we will include these studies. We will include studies of people
of all ages that report subgroup findings for elderly people (over 65
or 70 years of age) provided the participants in the subgroup num-
ber more than 20. We will consider including the mixed data if it
is clear that 80% or more of participants in the study are over the
age of 65 years. Similarly, where the study population includes both
grade 3 or 4 gliomas (anaplastic astrocytomas or glioblastoma), we
will try to obtain separate data for participants with glioblastoma;
if this is not possible, we will consider including the study if more
than half the study population had glioblastoma.
Types of interventions
Interventions to be evaluated alone or in combination with each
other versus any of the other interventions include the following.
• Radiotherapy (standard, hypofractionated, and other tech-
niques).• Chemotherapy (TMZ and other types).
We will include all available regimens of radiotherapy and
chemotherapy that have been evaluated in randomised trials. If we
identify interventions in the included studies of which we are not
aware, we will consider including them after we assess their com-
parability with those interventions named above. We will exclude
phase 1 and 2 studies of novel interventions that have been shown
to be detrimental and have not been developed further. The antic-
ipated network graph is in Figure 1.
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Figure 1.
 
We will create separate networks according to the type of surgi-
cal procedure (GTR, STR, and biopsy only). Within each of these
networks we will assume that any participants within the network
could be randomised to any of the interventions e.g. an elderly per-
son with histologically confirmed glioblastoma could be equally
likely to be randomised to standard radiotherapy, chemotherapy,
any combination of these or supportive care.
Types of outcome measures
Primary outcomes• Overall survival (time from randomisation to death from any
cause).• Quality of life (QoL), as measured using a standardised question-
naire, e.g. the European Organisation for Research and Treat-
ment of Cancer (EORTC) QLQ-C30 or QLQ-BN20 (specific for brain
cancer), or the Functional Assessment of Cancer Therapy scale
(FACT-G [general] or FACT-Br [specific for brain cancer]).
Secondary outcomes• Progression-free survival (time from randomisation to disease
progression or death from any cause).• Severe adverse events, according to standardised scales, e.g.
Common Terminology Criteria for Adverse Events (CTCAE).• Cognitive impairment (objective or subjective), as measured by
an overall cognitive function score, as a change-over-time score,
or reported as individual cognitive function domains, e.g. ver-
bal fluency, processing speed, memory, attention, and execu-
tive functioning, using a standardised measurement tool, e.g.
Mini Mental State Exam (MMSE), EORTC, FACT.
• Functional impairment or disability, as measured by an overall
ability score and/or as a change of ability over time score using
a standardised measurement tool, e.g., Karnofsky Performance
Status Scale, Neurological Functions Score, EORTC, FACT; or as
a categorical outcome as defined by investigators.• Fatigue, according to CTCAE, EORTC, or as defined by investiga-
tors.• Economic outcomes:* Resource use for health care.* Health state utilities.* Costs of health care.* Incremental cost-effectiveness.* Resource use for health care.* Health state utilities.* Costs of health care.* Incremental cost-effectiveness.
Search methods for identification of studies
Electronic searches
1. For studies on the effects of the interventions, we will search the
following databases.
• The Cochrane Central Register of Controlled Trials (CENTRAL;
latest issue), in the Cochrane Library.• MEDLINE via Ovid (from 1946).• Embase via Ovid (from 1980).
2. For economic evidence we will search the following.
• MEDLINE via Ovid (from 1946).
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• Embase via Ovid (from 1980).• NHS Economic Evaluation Database (EED).
The EED database will be searched up to the end of December 2014
(when the last records were added to that database) and MEDLINE
and Embase from 1 January 2015, as the NHS EED already includ-
ed comprehensive searches of these databases prior to 2015. We
will also consider relevant grey literature (such as health technolo-
gy assessments, reports, and working papers) for inclusion.
Please refer to Appendix 1 for the MEDLINE search strategy.
We will not apply language restrictions to any literature searches.
Searching other resources
We will search the following for ongoing trials.
• ClinicalTrials.gov (clinicaltrials.gov/).• WHO International Clinical Trials Registry Platform (ICTRP) (app-
s.who.int/trialsearch/).
If ongoing trials that have not been published are identified through
these searches, we will approach the principal investigators to ask
for an update on the trial status and any relevant unpublished data,
if available.
We will use the related articles feature of PubMed and handsearch
the reference lists of included studies to identify newly published
articles and additional studies of relevance. We do not intend to
handsearch journals and conference proceedings as, in our expe-
rience, it is resource intensive and yields of additional studies not
already identified by electronic searches tend to be very low.
Data collection and analysis
Selection of studies
For the results of search 1 (trials of effectiveness and safety), the In-
formation Specialist at the Cochrane Gynaecological, Neuro-oncol-
ogy and Orphan Cancer Group (CGNOC) will download all titles and
abstracts retrieved by electronic searching to EndNote X8 and will
remove duplicates. Two review authors (TAL, CRH, or ER) will inde-
pendently screen the remaining records and exclude studies that
clearly do not meet the eligibility criteria. For potentially eligible
records, copies of the full texts will be obtained and two review au-
thors (TAL and CRH) will independently assess them for eligibility.
The two review authors will resolve any disagreements through dis-
cussion and, if necessary, will consult at least one other review au-
thor. We will use Covidence to facilitate this study selection process
and will document the reasons for exclusion of studies accordingly.
To inform the economic outcomes full economic evaluations
(cost-effectiveness analyses, cost-utility analyses, and cost-bene-
fit analyses), we will consider cost analyses and comparative re-
source-utilisation studies. Studies carried out alongside relevant
RCTs and model-based studies will be considered for inclusion. Two
review authors (LV and AK) will independently screen for eligible
studies.
Data extraction and management
Two review authors (TAL, CRH, or ER) will independently extract da-
ta from included studies using a pre-designed data extraction form
(Higgins 2011). We will extract the following data.
• Author contact details.• Country.• Setting.• Dates of participant accrual.• Funding source.• Inclusion and exclusion criteria.• Study design.• Study population and baseline characteristics:* Number of participants enrolled.* Number of participants analysed.* Age.* Gender.• Potential effect modifiers:* Molecular type of glioblastoma.* Performance status.• Intervention details:* Type of intervention, dose, timing, and other regimen details.* Type of comparator.• Risk of bias assessment (see below).• Duration of follow-up.• Primary outcome(s) of the study.• Review outcomes:* For time-to-event outcomes (overall and progression-free
survival) we will extract the hazard ratio (HR) with its 95%
confidence interval for time points as reported by the study
authors. We will note the definition of and procedure used to
identify progression. Where reported, we will also extract di-
chotomous data for these outcomes at author specified time-
points.* For dichotomous outcomes (e.g. serious adverse events), we
will extract the number of participants in each treatment arm
that experienced the outcome of interest and the number of
participants assessed.* For continuous outcomes (e.g. QoL scores), we will extract
the value and standard deviation of the outcome of inter-
est and the number of participants assessed at the relevant
time-point in each group. We will also extract change-from-
baseline score data where reported and note the type of scale
used.* We will extract adjusted statistics where reported.* Where possible, all data extracted will be those relevant
to an intention-to-treat analysis, in which participants were
analysed in the groups to which they were assigned.* We will resolve differences between review authors by dis-
cussion or by appeal to a third review author when necessary.
Assessment of risk of bias in included studies
We will assess the risk of bias using Cochrane's ‘Risk of bias' tool
and the criteria specified in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). This includes assessment
of:
• Random sequence generation.• Allocation concealment.• Blinding of participants and healthcare providers.• Blinding of outcome assessors.
Treatment of newly diagnosed glioblastoma in the elderly (Protocol)
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• Incomplete outcome data (more than 20% missing data consid-
ered high risk).• Selective reporting of outcomes.• Other possible sources of bias, e.g. lack of a power calculation,
baseline differences in group characteristics.
Two review authors (TAL and CRH) will independently assess risk of
bias and will resolve any differences in opinion by discussion or by
consulting a third review author. We will summarise judgements in
‘Risk of bias' tables along with the characteristics of the included
studies. We will interpret the results of meta-analyses in light of the
overall ‘Risk of bias' assessment. For more details about the ‘Risk
of bias' assessment see Appendix 2.
We will assess economic evaluation studies for bias in two stages.
The first stage will involve assessing risk of bias from the sources of
the effectiveness data. In economic evaluations carried out along-
side clinical trials we will assess these using the Cochrane ‘Risk of
bias' tool, as described above. If the economic evaluation is mod-
el-based, we will use the ROBIS tool to assess bias in the effective-
ness studies (Whiting 2016). The second stage involves assessing
the risk of bias of the economic evidence (i.e. assessing the overall
methodological quality). This will be done using the CHEERS check-
list (Husereau 2013).
Measures of treatment e:ect
Eectiveness data• For time-to-event outcomes (e.g. overall survival), we will ex-
tract the hazard ratio (HR) with its 95% confidence interval (CI).• For continuous outcomes (e.g. QoL scores) we assume that
study authors will use different measurement scales, therefore,
we plan to estimate the standardised mean difference (SMD)
and its 95% CI using the pooled data. However, if the same mea-
surement scale is used, we will estimate the mean difference
(MD) and its 95% CI. If studies do not report total values but, in-
stead, report change-from-baseline outcomes, we will combine
these change values with total measurement outcomes by using
the (unstandardised) mean difference method in Review Man-
ager 5 (RevMan 5) (RevMan 2014). We will use subgroups to dis-
tinguish between MDs of change scores and MDs of final values,
and pool the subgroups in an overall analysis (Higgins 2011).• For dichotomous outcomes, we will calculate the effect size as
a risk ratio (RR) with its 95% CI.
Economic data
Two review authors (AK and LV) will independently extract data
from relevant economic studies and summarise this information in
tables. We will extract data extracted on the following.
• Type of evaluations.• Sources of effectiveness data.• Cost data.• Sources of cost data.• Sources of outcome valuations.• Analytical approach.
Two review authors (AK and LV) will extract data on the economic
outcomes.
Unit of analysis issues
Two review authors (TAL and CRH) will assess unit of analysis issues
according to Higgins 2011, and will resolve any differences in opin-
ion by discussion. These include reports where there are multiple
observations for the same outcome (e.g. repeated measurements
with different scales or at different time-points, recurring events).
An example of where this might occur is with the outcome ‘quality
of life'. If meta-analysis is not feasible or meaningful, we will extract
data from all scales or time-points, or both; and, where possible,
will describe them narratively.
Multi-arm trials
We will include multi-arm trials in this review. We will treat mul-
ti-arm studies as multiple independent comparisons in pairwise
meta-analyses. However, in the network meta-analysis we will ac-
count for the correlation between the effect sizes derived from the
same study.
Dealing with missing data
We will not impute missing data. In the event of missing data, we
will write to study authors to request the data on primary outcomes
and describe in the ‘Characteristics of included studies' tables how
any missing data were obtained.
Assessment of heterogeneity
Assessment of clinical and methodological heterogeneity
We will assess clinical heterogeneity between studies by comparing
between the studies characteristics of included participants, and
interventions in each meta-analysis of each comparison, by visual
inspection of forest plots, by estimation of the percentage hetero-
geneity between trials which cannot be ascribed to sampling varia-
tion (Higgins 2003), by a formal statistical test of the significance of
the heterogeneity (Deeks 2001), and, where possible, by subgroup
analyses. If there is evidence of substantial heterogeneity, we will
investigate and report the possible reasons for this.
Assessment of consistency across treatment comparisons
We will examine the assumption of consistency by assessing the
distribution of potential effect modifiers across the pair-wise com-
parisons. The assumption will hold if the following is true.
• The common treatment used to compare different interventions
indirectly is similar when it appears in different trials.• All pairwise comparisons do not differ with respect to the distri-
bution of effect modifiers.
Assessment of statistical heterogeneity and inconsistency
Assumptions when estimating the heterogeneity
In standard pairwise meta-analyses we will estimate different het-
erogeneity variances for each pairwise comparison. In network
meta-analysis, we will assume a common estimate for the hetero-
geneity variance across the different comparisons.
Measures and tests for heterogeneity
We will perform the presence of statistical heterogeneity within the
pairwise comparisons using the I2 statistic, which is the percentage
of variability that cannot be attributed to random error.
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We will base the assessment of statistical heterogeneity in the net-
work on the magnitude of the heterogeneity variance parameter
(τ2) estimated from the network meta-analysis models.
Assessment of statistical inconsistency
We will evaluate the statistical agreement between the various
sources of evidence in a network of interventions (consistency) by
global and local approaches to complement the evaluation of con-
sistency.
Assessment of reporting biases
If there are 10 or more studies included in meta-analyses, we will
investigate reporting biases (such as publication bias) using funnel
plots. We will assess funnel plot asymmetry visually. If asymmetry
is suggested by a visual assessment, we will perform exploratory
analyses to investigate it.
Data synthesis
Methods for direct treatment comparisons
We will perform standard pair-wise meta-analyses for each com-
parison using a random-effects model.
Methods for indirect and mixed comparisons
We will conduct network meta-analyses if we consider participants,
comparisons, and outcomes to be sufficiently similar to ensure an
answer that is clinically meaningful (see illustrative network Fig-
ure 1). We plan to use the random-effects model in STATA fitting a
multivariate network meta-analysis (White 2015), and other STATA
commands for visualising and reporting results in network meta-
analysis (Chaimani 2015); alternatively we might use WinBUGS in a
Bayesian framework (Lunn 2000).
We will attempt to synthesize narrative summaries of outcomes for
which meta-analysis is not possible, due to the different ways that
investigators have reported or measured outcomes, and assess
these using the GRADE approach (Murad 2017). We will interpret
the quality of the evidence based on the Cochrane Effective Prac-
tice and Organisation of Care (EPOC) Group's guidance (Cochrane
EPOC 2015).
We will summarize characteristics and results of included econom-
ic evaluations using additional tables, supplemented by a narrative
summary that will compare and evaluate methods used and prin-
cipal results between studies. Unit cost data will also be tabulated,
when available. We will report the currency and price year applica-
ble to measures of costs in each original study alongside measures
of costs, incremental costs, and incremental cost-effectiveness by
study. Where details of currency and price year are available in orig-
inal studies, we will convert measures of costs, incremental costs,
and cost-effectiveness to (latest year) international dollars value
using implicit price deflators for gross domestic product (GDP) and
GDP Purchasing Power Parities (EPPI Centre Cost Converter 2016).
Details of the methodological characteristics of individual included
health economics studies will be summarised in ‘Characteristics of
included studies’ tables. All elements of the economics component
of this review will be conducted according to current guidance on
the use of economics methods in the preparation and maintenance
of Cochrane reviews (Higgins 2011; Shemilt 2018; Wijnen 2016).
‘Summary of findings' tables and results reporting
E:ectiveness summary of findings• For time-to-event outcomes (e.g. overall survival), we will calcu-
late the observed minus expected events (O minus E) and vari-
ance from the reported time–to-event estimates to obtain the
log hazard ratio (LnHR) and standard error (SE) of LnHR. We will
report the summary estimates as hazard ratios (HR) with its 95%
confidence intervals (CI).• For continuous outcomes (e.g. QoL scores), we assume that
study authors will use different measurement scales. Therefore,
we plan to estimate the standardised mean difference (SMD)
and its 95% CI using the pooled data. However, if the same mea-
surement scale is used, we will estimate the mean difference
(MD) and its 95% CI. If studies do not report total values but in-
stead report change-from-baseline outcomes, we will combine
these change values with total measurement outcomes by us-
ing the (unstandardised) mean difference method in RevMan 5
(RevMan 2014).• For dichotomous outcomes, we will summarise data as a risk ra-
tio (RR) with 95% CI.
We will create the ‘Summary of findings' tables using GRADEpro
Guideline Development Tool (GDT) software (GRADEpro 2015). The
summary tables will be designed following the approach suggested
by Schunemann 2009 and Puhan 2014. We will provide justification
for each assessment about the confidence in the estimates of effect
(e.g. reasons for downgrading the quality of the evidence). If meta-
analysis is not possible, we will present the results in a narrative
‘Summary of findings' table. Two review authors will independent-
ly assess the quality of the evidence. We will resolve any differences
of opinion by discussion and, if necessary, by consulting a third re-
view author.
Relative treatment ranking
We will compute ranking of probabilities for all included treatments
and obtain a treatment hierarchy using the surface under the cu-
mulative ranking curve (SUCRA). For primary outcomes, we will as-
sess the robustness of these findings in sensitivity analysis by con-
sidering estimates of mean rank with 95% CIs.
Economic evaluation summary of findings
For the economic evaluation studies, we will present the following
findings in a table.
• Method of economic evaluation.• Costs.• Outcomes.• Incremental cost effectiveness ratio.
Subgroup analysis and investigation of heterogeneity
If study investigators use different age thresholds to define the el-
derly, and if data are sufficient, we will perform subgroup analy-
sis by these thresholds. We will use formal tests for subgroup dif-
ferences to determine whether the effect of interventions differ ac-
cording to these subgroups. Depending on these findings, we will
consider whether an overall summary is meaningful.
We will consider the baseline characteristics of study participants
and risk of bias in the interpretation of any heterogeneity. If we
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identify substantial heterogeneity, we will investigate it in sensitiv-
ity analyses.
Sensitivity analysis
We will perform sensitivity analysis to investigate statistical hetero-
geneity identified in meta-analyses of primary outcomes and also
to evaluate the effect after excluding studies at high risk of bias, to
investigate how trial quality affects the certainty of the findings. We
will also perform a sensitivity analysis by excluding trials that in-
clude mixed participant data.
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A P P E N D I C E S
Appendix 1. Search strategies
MEDLINE search strategy for e:ectiveness evidence
1. Glioblastoma/
2. (glioblastoma* or Glioblastoma* or GB* or astrocyt*).ti,ab.
3. 1 or 2
4. exp Aged/
5. (aged* or old* or ageing* or geriatric*).ti,ab.
6. (elder* or "over 60" or "over 65" or "over 70" or "over 80" or "over 85" or "60 year*" or "65 year*" or "70 year*" or "80 year" or "85
year*").ti,ab.
7. 4 or 5 or 6
8. 3 and 7
9. Neurosurgery/
10. surgery.fs.
11. (surg* or neurosurg* or craniotomy* or resect* or EOR* or intraoperative*).mp.
12. exp Radiotherapy/
13. radiotherapy.fs.
14. (radiotherap* or RT or radiat* or irradiat*).ti,ab.
15. exp Antineoplastic Agents/
16. Antineoplastic Combined Chemotherapy Protocols/
17. (temozolomide or TMZ or Temodal or Temodar or Temodal or Temcad* or chemotherap* or procarbazine or Lomustine or CCNU or
vincristine or PCV or cisplatinum or carboplatinum).mp.
18. exp Chemoradiotherapy/
19. (radiochemo* or chemoradio*).mp.
20. exp immunotherapy/
21. immunotherap*.mp.
22. exp steroids/
23. (dexamethasone or prednisolone or methylprednisolone).mp.
24. 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25. 8 and 24
26. randomized controlled trial.pt.
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27. controlled clinical trial.pt.
28. randomized.ab.
29. placebo.ab.
30. clinical trials as topic.sh.
31. randomly.ab.
32. trial.ti
33. 26 or 27 or 28 or 29 or 30 or 31 or 32
34. (animals not (humans and animals)).sh.
35. 33 not 34
36. 25 and 35
MEDLINE search strategy for economic evidence
1. Glioblastoma/
2. (glioblastoma* or Glioblastoma* or GB* or astrocyt*).ti,ab.
3. 1 or 2
4. exp Aged/
5. (aged* or old* or ageing* or geriatric*).ti,ab.
6. (elder* or "over 60" or "over 65" or "over 70" or "over 80" or "60 year*" or "65 year*" or "70 year*" or "85 year*").ti,ab.
7. 4 or 5 or 6
8. 3 and 7
9. Neurosurgery/
10. surgery.fs.
11. (surg* or neurosurg* or craniotomy* or resect* or EOR* or intraoperative*).mp.
12. exp Radiotherapy/
13. radiotherapy.fs.
14. (radiotherap* or RT or radiat* or irradiat*).ti,ab
15. exp Antineoplastic Agents/
16. Antineoplastic Combined Chemotherapy Protocols/
17. (temozolomide or TMZ or Temodal or Temodar or Temodal or Temcad* or chemotherap* or procarbazine or Lomustine or CCNU or
vincristine or PCV or cisplatinum or carboplatinum).mp.
18. exp Chemoradiotherapy/
19. (radiochemo* or chemoradio*).mp.
20. exp IMMUNOTHERAPY/
21. immunotherap*.mp.
22. exp STEROIDS/
23. (dexamethasone or prednisolone or methylprednisolone).mp.
24. 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25. 8 and 24
26. Economics/
27. exp "costs and cost analysis"/
28. Economics, Dental/
29. exp economics, hospital/
30. Economics, Medical/
31. Economics, Nursing/
32. Economics, Pharmaceutical/
33. (economic$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,ab.
34. (expenditure$ not energy).ti,ab.
35. value for money.ti,ab.
36. budget$.ti,ab.
37. 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36
38. ((energy or oxygen) adj cost).ti,ab.
39. (metabolic adj cost).ti,ab.
40. ((energy or oxygen) adj expenditure).ti,ab.
41. 38 or 39 or 40
42. 37 not 41
43. letter.pt.
44. editorial.pt.
45. historical article.pt.
46. 43 or 44 or 45
47. 42 not 46
48. 25 and 47
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key:
mp=title, original title, abstract, name of substance word, subject heading word
pt=publication type
ab=abstract
fs= floating subheading
sh=Medical Subject Heading
Similar strategies were devised for Embase.
Appendix 2. ‘Risk of bias' assessment
We will assess the risk of bias according to the following criteria.
1. Random sequence generation• Low risk of bias e.g. participants assigned to treatments on basis of a computer-generated random sequence or a table of random
numbers• High risk of bias e.g. participants assigned to treatments on basis of date of birth, clinic identification-number or surname, or no attempt
to randomise participants• Unclear risk of bias e.g. not reported, information not available
2. Allocation concealment• Low risk of bias e.g. where the allocation sequence could not be foretold• High risk of bias e.g. allocation sequence could be foretold by patients, investigators or treatment providers• Unclear risk of bias e.g. not reported
3. Blinding of participants and personnel• Low risk of bias if participants and personnel were adequately blinded• High risk of bias if participants or personnel, or both, were not blinded to the intervention that the participant received• Unclear risk of bias if this was not reported or unclear
4. Blinding of outcomes assessors• Low risk of bias if outcome assessors were adequately blinded to the intervention that the participant received• High risk of bias if outcome assessors were not blinded to the intervention that the participant received• Unclear risk of bias if this was not reported or unclear
5. Incomplete outcome data
We will record the proportion of participants whose outcomes were not reported at the end of the study. We will code a satisfactory level
of loss to follow-up for each outcome as follows.
• Low risk of bias, if fewer than 20% of patients were lost to follow-up and reasons for loss to follow-up were similar in both treatment arms• High risk of bias, if more than 20% of patients were lost to follow-up or reasons for loss to follow-up differed between treatment arms• Unclear risk of bias if loss to follow-up was not reported
6. Selective reporting of outcomes• Low risk of bias e.g. review reports all outcomes specified in the protocol• High risk of bias e.g. it is suspected that outcomes have been selectively reported• Unclear risk of bias e.g. it is unclear whether outcomes had been selectively reported
7. Other bias• Low risk of bias, i.e. no other source of bias suspected and the trial appears to be methodologically sound• High risk of bias, if we suspect that the trial was prone to an additional bias• Unclear risk of bias, if we are uncertain whether an additional bias may have been present
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